Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Income from Continuing Operations of 147758000.0 for Q1 2026, down 36.76% on a QoQ basis from 108039000.0 in Q4 2025, and down 32.56% year-over-year from 219091617.15 in Q1 2025.
Agios Pharmaceuticals (AGIO) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 147758000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 32.56% year-over-year to 147758000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 491197000.0 (down 178.04% YoY) and the FY2025 annual result came in at 412781000.0, down 161.27% from the prior year.
- Income from Continuing Operations was 147758000.0 for Q1 2026 at Agios Pharmaceuticals, down from 108039000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 947915000.0 in Q3 2024 and bottomed at 147758000.0 in Q1 2026.
- A 5-year average of 42122117.65 and a median of 97109000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 1137.97% — and 2025, when it plunged 110.91%.
- Agios Pharmaceuticals' Income from Continuing Operations stood at 97109000.0 in 2022, then rose by 1.2% to 95940000.0 in 2023, then slipped by 0.61% to 96523000.0 in 2024, then fell by 11.93% to 108039000.0 in 2025, then plunged by 36.76% to 147758000.0 in 2026.
- Business Quant data shows AGIO's Income from Continuing Operations at 147758000.0 in Q1 2026, 108039000.0 in Q4 2025, and 103433000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -147.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.76 Mn |
| Dec 31, 2025 | -108.04 Mn |
| Sep 30, 2025 | -103.43 Mn |
| Jun 30, 2025 | -131.97 Mn |
| Mar 31, 2025 | -111.47 Mn |
| Dec 31, 2024 | -96.52 Mn |
| Sep 30, 2024 | 947.92 Mn |
| Jun 30, 2024 | -110.50 Mn |
| Mar 31, 2024 | -96.73 Mn |
| Dec 31, 2023 | -95.94 Mn |
| Sep 30, 2023 | -91.32 Mn |
| Jun 30, 2023 | -89.99 Mn |
| Mar 31, 2023 | -87.04 Mn |
| Dec 31, 2022 | -97.11 Mn |
| Sep 30, 2022 | -91.69 Mn |
| Jun 30, 2022 | -100.26 Mn |
| Mar 31, 2022 | -104.23 Mn |
| Dec 31, 2021 | -98.58 Mn |
| Sep 30, 2021 | -84.26 Mn |
| Jun 30, 2021 | -82.79 Mn |